Negative Pressure Wound Therapy (NPWT) — also known as Vacuum-Assisted Closure (VAC) — applies sub-atmospheric pressure to a wound bed via a sealed foam dressing connected to a vacuum device. The continuous or intermittent negative pressure removes excess exudate, promotes granulation tissue formation, reduces oedema, and accelerates wound healing.
Core Principle: By applying pressure below atmospheric (typically 80–125 mmHg below ambient), the wound environment is optimised for cellular repair — removing barriers to healing while mechanically stimulating tissue growth.
The foam collapses under negative pressure, drawing wound edges together. This mechanical contraction reduces the wound surface area and promotes approximation of wound margins — particularly useful in large open wounds.
At a cellular level, mechanical stress is transmitted to individual cells via the foam-tissue interface. This cell stretching (mechanotransduction) triggers proliferation, migration, and angiogenesis — stimulating fibroblast and endothelial activity.
Excess exudate, inflammatory mediators, and proteases are continuously evacuated from the wound bed into the canister. This reduces wound oedema, lowers interstitial pressure, and improves local perfusion and oxygen delivery.
Regular exudate removal reduces bacterial colonisation. Negative pressure promotes neovascularisation and angiogenesis by triggering vascular endothelial growth factor (VEGF) release. Blood vessel density in granulating tissue increases measurably.
In GCC, diabetic foot wounds are the primary NPWT indication — high prevalence of Type 2 DM across Gulf states drives demand for wound care services.
Absolute Contraindications — DO NOT apply NPWT:
Relative Contraindications — use with caution / senior review:
Closed incision management — post-operative high-risk incisions (obese patients, high tension wounds, orthopaedic incisions). Reduces surgical site infection and dehiscence risk. Pressure typically 80 mmHg, run for 7 days post-operatively.
Open wounds with significant exudate requiring active collection. Granulating wound beds requiring foam contact and mechanical stimulation. Canister fill monitored and changed at 75–80% capacity to prevent backflow.
NPWT does not replace wound bed preparation. The wound must be adequately debrided, irrigated, and infection controlled before NPWT application — negative pressure over sloughy, necrotic, or untreated infected tissue will not produce effective healing.
Irrigate with sterile saline or suitable wound irrigation solution. Remove surface debris and loose material. Avoid cytotoxic antiseptics (povidone-iodine, hydrogen peroxide) directly in granulating wounds.
Remove necrotic tissue and slough using surgical, autolytic, or enzymatic debridement as appropriate. Dry eschar must be debrided before NPWT — eschar prevents foam contact and suction effect.
Measure wound dimensions (length × width × depth in cm). Note undermining or tunnelling. Photograph wound. Identify exposed structures (tendons, vessels, bone) requiring protective interface before foam placement.
Constant negative pressure. Standard mode for most wounds. Better exudate removal. Preferred initially.
On/off cycles. May enhance angiogenesis. Consider for painful wounds or to reduce discomfort during therapy.
Used when the canister/device cannot be positioned close to the wound (e.g., perineal wounds, gluteal wounds). A strip of foam is placed outside the wound, covered by drape, extending from the wound foam to a flat skin area where the TRAC pad is applied. This "bridge" transmits negative pressure while allowing device positioning away from the wound site.
Clean granulating wounds, chronic wounds responding to therapy. Allows adequate time for granulation without excessive tissue ingrowth.
Wounds with active infection or high bacterial load. More frequent changes reduce biofilm formation and allow wound reassessment.
Leave undisturbed to maximise graft take. First dressing change at day 3–5 unless complication suspected. Minimise patient movement.
GCC Note: High ambient temperatures in Gulf states increase patient perspiration and wound exudate production — reassess dressing change frequency accordingly. Canister may fill faster in hot weather.
Pain Management First: Pre-medicate 30 minutes before dressing change. Options include oral opioid analgesia, oral morphine solution, or Entonox (50% N₂O/O₂) inhaled during procedure. This is mandatory for patient comfort and compliance.
Expect to see within 2 weeks of effective NPWT:
On initiating suction, the wound edges should visibly draw together within 30–60 seconds — this confirms good seal and effective therapy.
Escalate to wound care specialist or medical team if:
NPWT is not appropriate for all wounds. Non-response prompts wound re-evaluation, biopsy consideration, and reassessment of underlying cause (ischaemia, ongoing infection, inadequate debridement).
A leak means therapy is not running at prescribed pressure. The device will alarm. A systematic approach to leak identification resolves most cases without removing the whole dressing.
Bright red blood in canister or bleeding at wound = STOP THERAPY IMMEDIATELY
NPWT does not sterilise wounds. It reduces bacterial load, but active infection requires specific management — NPWT alone is not adequate treatment for clinical infection.
High-complexity procedure — requires specialist surgical and wound care team. Open abdomen NPWT is used in damage control surgery, abdominal compartment syndrome, or peritonitis with planned re-look laparotomy.
NPWT as a bolster dressing over skin grafts dramatically improves graft take by eliminating shear, reducing seroma/haematoma formation, and maintaining close contact between graft and recipient bed.
Post-cardiac surgery sternal wound dehiscence (mediastinitis) is a serious complication with high mortality if untreated. NPWT has transformed management of this condition, bridging to surgical reconstruction.
Any sudden change in cardiac status or respiratory function in a sternal NPWT patient requires immediate medical review — do not delay.
Paediatric NPWT requires careful adaptation. Standard adult settings and foam sizes are inappropriate for small children and neonates.
Diabetes prevalence in Gulf states (UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman) is among the highest globally — 12–20% of adult populations. Diabetic foot ulceration and complications are therefore the leading NPWT indication across GCC healthcare facilities.
Extreme heat and high humidity in GCC — especially summer months (40–50°C outdoors). This results in increased wound exudate production, accelerated bacterial growth, and faster canister fill. Periwound skin moisture and maceration risk is higher. Increase vigilance for drape leaks and periwound breakdown.
NPWT is available across tertiary hospitals in UAE (DHA, DOH), Saudi Arabia (MOH, NGHA), Qatar (HMC), Kuwait, Bahrain, and Oman. Community NPWT is expanding. Nursing competency frameworks (DHA nursing scope, SCFHS, QCHP) include wound care and NPWT within wound care nurse scope of practice.
| Category | Indicated / Suitable | Relative CI — Caution | Absolute CI — Do Not Use |
|---|---|---|---|
| Wound tissue | Granulating, clean, post-debridement | Partial slough with debridement ongoing | Dry eschar (not debrided), necrosis |
| Bleeding | Haemostasis achieved | Anticoagulated patient — use lower pressure | Active / uncontrolled haemorrhage |
| Infection | Colonised wounds, post-antibiotic | Cellulitis — treat first, monitor closely | Untreated osteomyelitis |
| Malignancy | No malignancy in wound | Known malignancy elsewhere — MDT decision | Malignancy in wound bed |
| Fistula | Fistula fully explored and mapped | Known fistula — protect, use carefully | Unexplored fistulae |
| Exposed structures | Structures covered by granulation/fascia | Exposed tendon/bone — use white foam + interface | Exposed vessel/organ without protection |
| Feature | Black PU Foam | White PVA Foam |
|---|---|---|
| Pore size | 400–600 microns (large) | Small pores |
| Microdeformation | Aggressive / high stimulation | Gentle / low stimulation |
| Fluid transfer | Higher | Lower |
| Tissue ingrowth risk | Higher (change ≤72h) | Low |
| Removal pain | More (ingrowth) | Less |
| Premoistening needed | No | Yes (saline) |
| Best for | Standard granulating, deep wounds | Tunnelling, near vessels/tendons, grafts, fragile tissue |
NPWT mechanisms: Macrodeformation + Microdeformation + Fluid removal + Bacterial reduction + Angiogenesis promotion
Wound edge contraction within 30–60 seconds of starting therapy = confirms correct seal and effective suction
Bright red blood in canister = STOP therapy immediately, do not restart until haemorrhage is controlled
Diabetic foot ulcers = primary NPWT indication in GCC — examiner context question